SureTrader Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, HorseShoe Man
Search This Board:
Last Post: 11/25/2015 10:42:08 AM - Followers: 558 - Board type: Free - Posts Today: 3

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Quarterly Report (10-q) 10/15/2015 06:07:03 AM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:10:34 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:09:13 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:07:11 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:05:40 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#41065   Global Antibody Drug Conjugate Market Outlook 2020 TraderpennyX 11/25/15 10:42:08 AM
#41064   Gee, can somebody help me out? I simon wagstaff 11/25/15 09:47:47 AM
#41063   We know that Oxis Biotech is working with Mcit. bontooth 11/25/15 02:41:28 AM
#41061   Ya that is MCT-465 or 485 forgot the number sup105 11/23/15 11:59:50 PM
#41060   I remember They listed on the 10-Q How sup105 11/23/15 11:55:00 PM
#41059   I thought that we were doing breast cancer research. The dead cat bouncer 11/23/15 11:46:18 PM
#41058   This news is money in the bank for HorseShoe Man 11/23/15 08:36:48 PM
#41057 ctvette2003 11/23/15 05:48:05 PM
#41056   OXIS BORROWED MCET PATENT PROCESS TO PHASE 1/2 sup105 11/23/15 04:22:24 PM
#41055   Link please~!! sup105 11/23/15 04:20:36 PM
#41054   Waiting for this 11 million dollar payday PR. HorseShoe Man 11/23/15 11:49:26 AM
#41053   OXIS just got approvals for phase I II HorseShoe Man 11/23/15 11:24:44 AM
#41052 mrroundtree 11/21/15 04:01:53 PM
#41051   lol that's hilarious. Those paintings are worth more Dip66 11/21/15 09:39:11 AM
#41050   I wonder who is in Newmin's will? simon wagstaff 11/21/15 09:14:23 AM
#41049   You should really consider teaming up with the bontooth 11/21/15 03:59:01 AM
#41048   16 million shares dumped? Looks like Newmin took Dip66 11/19/15 01:27:54 PM
#41047   Trading is starting off early with a bang HorseShoe Man 11/19/15 09:49:20 AM
#41046   Another old saying "The best things come to HorseShoe Man 11/19/15 08:42:44 AM
#41045   Another old saying "Scared money never prospers" MCET's HorseShoe Man 11/19/15 08:33:49 AM
#41044   Another old saying "A fool and his money simon wagstaff 11/19/15 07:50:54 AM
#41043   Does that pertain to Post #: 41021 bontooth 11/19/15 05:32:51 AM
#41042   Funny trading today? I think it is going HorseShoe Man 11/18/15 04:39:17 PM
#41041   Theres an old saying. If you have nothing Dip66 11/18/15 03:08:31 PM
#41040   Oh yet kule1987 11/18/15 11:25:21 AM
#41039   76 shares so far today? What is that, simon wagstaff 11/18/15 11:24:02 AM
#41038   la jolla don't have the juice to move Dip66 11/18/15 10:05:45 AM
#41037   wow. RU talking to Horse? bontooth 11/18/15 02:32:39 AM
#41036   All in favor say aye <voting> ... bontooth 11/18/15 02:29:27 AM
#41035   wait wait kule1987 11/18/15 12:20:48 AM
#41034   I think this is going to be the HorseShoe Man 11/17/15 03:41:03 PM
#41033   SHE'S GOING! HorseShoe Man 11/17/15 03:37:12 PM
#41032   Strap up for the ride. Go to get HorseShoe Man 11/17/15 02:45:45 PM
#41031   After all patience do pay =) News incoming sup105 11/17/15 01:55:31 PM
#41030   Party in Aruba! Where's webby? Oneeyedpete 11/17/15 01:24:07 PM
#41029   Buckle Up! For safety purposes bontooth 11/17/15 01:21:27 PM
#41028   Watch the volume! MCET is getting ready HorseShoe Man 11/17/15 01:14:55 PM
#41027   MM's are filling orders! She getting ready to HorseShoe Man 11/17/15 12:35:33 PM
#41026   You're hilarious. mrroundtree 11/17/15 12:22:54 PM
#41025   This could be the start??!! HorseShoe Man 11/17/15 12:01:13 PM
#41024   Watching this one very close. This could HorseShoe Man 11/17/15 11:56:58 AM
#41023   This is going to explode!! HorseShoe Man 11/17/15 11:39:31 AM
#41022   .0004 is going to look really good when HorseShoe Man 11/17/15 11:14:25 AM
#41021   This company is a disgrace. Not even sure Dip66 11/17/15 10:04:44 AM
#41020   All depends on the PR. If I HorseShoe Man 11/16/15 06:28:52 PM
#41019   500k trade. Added to my 60 mil. Oneeyedpete 11/16/15 12:29:56 PM
#41018   It is indeed …. ferenc 11/16/15 12:16:10 PM
#41017   Someone needs to sell that small amount sitting bontooth 11/16/15 11:48:18 AM
#41016   Zero volume. Pathetic. simon wagstaff 11/16/15 10:27:14 AM